Placental disease and the maternal syndrome of preeclampsia: Missing links?

Current Hypertension Reports

Volumn 15, Issue 6, 2013, Pages 590-599

  Tannetta, Dionne ^a   Sargent, Ian ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Alarmins; Coagulation; Endothelium; Exosomes; Gasotransmitters; Hypertension; Inflammation; Microvesicles; Placenta; PlGF; Preeclampsia; sEng; sFlt 1; Syncytiotrophoblast; Tissue factor

Indexed keywords

ACTIN; ADENOSINE TRIPHOSPHATE; CARBON MONOXIDE; ENDOGLIN; HEAT SHOCK PROTEIN 70; HEMOGLOBIN F; HYDROGEN SULFIDE; NITRIC OXIDE; PLACENTAL GROWTH FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S100B; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; ENDOPLASMIC RETICULUM STRESS; ENDOTHELIAL DYSFUNCTION; EXOSOME; FIBRIN DEPOSITION; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLACENTA CIRCULATION; PLACENTA DISORDER; PLACENTA PERFUSION; PREECLAMPSIA; SYNCYTIOTROPHOBLAST;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERTENSION; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROTEINURIA;

EID: 84890082633     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0395-7     Document Type: Article

References (107)

1. Milne F, Redman C, Walker J, Baker P, Bradley J, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ. 2005;330(7491):576-80.
2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-44.
3. Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in perinatology. 2009;33(3):130-7.
4. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Brit Med J. 2005;330(7491):565-7.
5. Isler CM, Rinehart BK, Terrone DA, Martin RW, Magann EF, et al. Maternal mortality associated with HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol. 1999;181(4):924-8.
6. Coppage KH, Sibai BM. Treatment of hypertensive complications in pregnancy. Curr Pharm Design. 2005;11(6):749-57.
7. Campbell OMR, Graham WJ, Series LMS. Maternal survival 2 - Strategies for reducing maternal mortality: getting on with what works. Lancet. 2006;368(9543):1284-99.
8. Nicolaides KH. Turning the Pyramid of Prenatal Care. Fetal Diagn Ther. 2011;29(3):183-96.
9. Khong TY, Dewolf F, Robertson WB, Brosens I. Inadequate Maternal Vascular-Response to Placentation in Pregnancies Complicated by Preeclampsia and by Small-for-Gestational-Age Infants. Brit J Obstet Gynaec. 1986;93(10):1049-59.
10. Smith SD, Dunk CE, Aplin JD, Harris LK, Jones RL. Evidence for Immune Cell Involvement in Decidual Spiral Arteriole Remodeling in Early Human Pregnancy. Am J Pathol. 2009;174(5):1959-71.
11. Knofler M, Pollheimer J. IFPA Award in Placentology Lecture: Molecular regulation of human trophoblast invasion. Placenta. 2012;33:S55-62.
12. Erlebacher A. Immunology of the Maternal-Fetal Interface. Annu Rev Immunol. 2013;31:387-411.
13. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. Bjog-Int J Obstet Gy. 2006;113(5):580-9.
14. Burton GJ, Yung HW, Cindrova-Davies T, Charnock-Jones DS. Placental Endoplasmic Reticulum Stress and Oxidative Stress in the Pathophysiology of Unexplained Intrauterine Growth Restriction and Early Onset Preeclampsia. Placenta. 2009;30:S43-8.
15. Roberts DJ, Post MD. The placenta in pre-eclampsia and intrauterine growth restriction. J Clin Pathol. 2008;61(12):1254-60.
16. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365(9461):785-99.
17. Redman CWG, Sacks GP, Sargent IL. Preeclampsia: An excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2):499-506.
18. Sargent IL, Borzychowski AM, Redman CWG. Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online. 2006;13(5):680-6.
19. Lynch AM, Salmon JE. Dysregulated Complement Activation as a Common Pathway of Injury in Preeclampsia and Other Pregnancy Complications. Placenta. 2010;31(7):561-7.
20. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension. Circulation. 2010;122(5):478-87.
21. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003;361(9368):1511-7.
22. Cockell AP, Poston L. Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension. 1997;30(2):247-51.
23. Bowyer L, Brown MA, Jones M. Forearm blood flow in pre-eclampsia. Bjog-Int J Obstet Gy. 2003;110(4):383-91.
24. Robb AO, Mills NL, Din JN, Smith IBJ, Paterson F, et al. Influence of the Menstrual Cycle, Pregnancy, and Preeclampsia on Arterial Stiffness. Hypertension. 2009;53(6):952-U115.
25. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, et al. Association of maternal endothelial dysfunction with preeclampsia. Jama-J Am Med Assoc. 2001;285(12):1607-12.
26. Meher S, Duley L. (2007) Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Db Syst Rev(2).
27. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol. 2007;18(8):2281-4.
28. • Craici IM, Wagner SJ, Bailey KR, Fitz-Gibbon PD, Wood-Wentz CM, et al. Podocyturia Predates Proteinuria and Clinical Features of Preeclampsia Longitudinal Prospective Study. Hypertension. 2013;61(6):1289-U343. A reliable and predictive biomarker of PE is needed to improve early detection of the disease. The results of this study suggest that the presence of podocytes in the urine during the second trimester of pregnancy was both more sensitive and specific than angiogenic markers at predicting subsequent development of preeclampsia.
29. Rosenkranz A, Hiden M, Leschnik B, Weiss EC, Schlembach D, et al. Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemostasis. 2008;99(2):331-7.
30. Bonnar J, Mcnicol GP, Douglas AS. (1971) Coagulation and Fibrinolytic Systems in Pre-Eclampsia and Eclampsia. Brit Med J.2(5752):12-&.
31. Janes SL, Goodall AH. Flow cytometric detection of circulating activated platelets and platelet hyper-responsiveness in pre-eclampsia and pregnancy. Clin Sci (Lond). 1994;86(6):731-9.
32. Zusterzeel PL, Rutten H, Roelofs HM, Peters WH, Steegers EA. Protein carbonyls in decidua and placenta of pre-eclamptic women as markers for oxidative stress. Placenta. 2001;22(2-3):213-9.
33. Lee H, Park H, Kim YJ, Kim HJ, Ahn YM, et al. Expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in human preeclamptic placenta: Possible implications in the process of trophoblast apoptosis. Placenta. 2005;26(2-3):226-33.
34. Sankaralingam S, Xu Y, Sawamura T, Davidge ST. Increased Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Expression in the Maternal Vasculature of Women With Preeclampsia Role for Peroxynitrite. Hypertension. 2009;53(2):270-U310.
35. Bannenberg GL, Vieira HLA. Therapeutic applications of the gaseous mediators carbon monoxide and hydrogen sulfide. Expert Opin Ther Pat. 2009;19(5):663-82.
36. Yang GD, Wu LY, Jiang B, Yang W, Qi JS, et al. H(2)S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322(5901):587-90.
37. Demir B, Demir S, Pasa S, Guven S, Atamer Y, et al. The role of homocysteine, asymmetric dimethylarginine and nitric oxide in pre-eclampsia. J Obstet Gynaecol. 2012;32(6):525-8.
38. Gielen S, Sandri M, Erbs S, Adams V. Exercise-Induced Modulation of Endothelial Nitric Oxide Production. Curr Pharm Biotechno. 2011;12(9):1375-84.
39. Huang LT, Hsieh CS, Chang KA, Tain YL. Roles of Nitric Oxide and Asymmetric Dimethylarginine in Pregnancy and Fetal Programming. Int J Mol Sci. 2012;13(11):14606-22.
40. Conde-Agudelo A, Althabe F, Belizan JM, Kafury-Goeta AC. Cigarette smoking during pregnancy and risk of preeclampsia: A systematic review. Am J Obstet Gynecol. 1999;181(4):1026-35.
41. Ahmed A. New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications. Thrombosis research. 2011;127:S72-5.
42. Tsuchihashi S, Fondevila C, Ma J, Ke BB, Zhai Y, et al. HO-1 cytoprotective and anti-inflammatory effects in hepatic ischemia/reperfusion injury are Toll-like receptor-4 independent. Am J Transplant. 2004;4:434-5.
43. Brennecke SP, Gude NM, DiIulio JL, King RG. Reduction of placental nitric oxide synthase activity in pre-eclampsia. Clin Sci. 1997;93(1):51-5.
44. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nature medicine. 2006;12(6):642-9.
45. Nakamura M, Sekizawa A, Purwosunu Y, Okazaki S, Farina A, et al. Cellular mRNA expressions of anti-oxidant factors in the blood of preeclamptic women. Prenatal Diag. 2009;29(7):691-6.
46. 2 S activity may contribute to the pathogenesis of PE.
47. Laskowska M, Laskowska K, Terbosh M, Oleszczuk J. A comparison of maternal serum levels of endothelial nitric oxide synthase, asymmetric dimethylarginine, and homocysteine in normal and preeclamptic pregnancies. Med Sci Monitor. 2013;19:430-7.
48. Roe ND, Ren J. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vascular pharmacology. 2012;57(5-6):168-72.
49. Holmlund U, Wahamaa H, Bachmayer N, Bremme K, Sverremark-Ekstrom E, et al. The novel inflammatory cytokine high mobility group box protein 1 (HMGB1) is expressed by human term placenta. Immunology. 2007;122(3):430-7.
50. Barut F, Barut A, Dogan Gun B, Kandemir NO, Aktunc E, et al. Expression of heat shock protein 70 and endothelial nitric oxide synthase in placental tissue of preeclamptic and intrauterine growth-restricted pregnancies. Pathology, research and practice. 2010;206(9):651-6.
51. Marinoni E, Di Iorio R, Gazzolo D, Lucchini C, Michetti F, et al. Ontogenetic localization and distribution of S-100beta protein in human placental tissues. Obstetrics and gynecology. 2002;99(6):1093-9.
52. Yang H, Wang HC, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukocyte Biol. 2005;78(1):1-8.
53. Schmidt AP, Tort ABL, Amaral OB, Schmidt AP, Walz R, et al. Serum S100B in pregnancy-related hypertensive disorders: A case-control study. Clin Chem. 2004;50(2):435-8.
54. Chekir C, Nakatsuka M, Noguchi S, Konishi H, Kamada Y, et al. Accumulation of advanced glycation end products in women with preeclampsia: possible involvement of placental oxidative and nitrative stress. Placenta. 2006;27(2-3):225-33.
55. Fukushima A, Kawahara H, Isurugi C, Syoji T, Oyama R, et al. Changes in serum levels of heat shock protein 70 in preterm delivery and pre-eclampsia. The journal of obstetrics and gynaecology research. 2005;31(1):72-7.
56. Bakker WW, Donker RB, Timmer A, van Pampus MG, van Son WJ, et al. Plasma hemopexin activity in pregnancy and preeclampsia. Hypertens Pregnancy. 2007;26(2):227-39.
57. Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic consequences of saturating the plasma scavenger system for actin. Proceedings of the National Academy of Sciences of the United States of America. 1990;87(4):1381-5.
58. Zhong XY, Gebhardt S, Hillermann R, Tofa KC, Holzgreve W, et al. Parallel assessment of circulatory fetal DNA and corticotropin-releasing hormone mRNA in early- and late-onset preeclampsia. Clin Chem. 2005;51(9):1730-3.
59. Zhong XY, Holzgreve W, Hahn S. The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy. 2002;21(1):77-83.
60. Reddy A, Zhong XY, Rusterholz C, Hahn S, Holzgreve W, et al. The effect of labour and placental separation on the shedding of syncytiotrophoblast microparticles, cell-free DNA and mRNA in normal pregnancy and pre-eclampsia. Placenta. 2008;29(11):942-9.
61. • Scharfe-Nugent A, Corr SC, Carpenter SB, Keogh L, Doyle B, et al. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. Journal of Immunology. 2012;188(11):5706-12. Cell-free fetal DNA circulates at higher levels in pregnancies complicated by PE. Here, the authors show that fetal DNA is proinflammatory, activating NFκB in human PBMC resulting in IL-6 production. In pregnant mice, fetal DNA induced fetal resorption and preterm birth through TLR9 as TLR-/- mice were protected from these effects. This study implicates fetal DNA in the systemic inflammatory response provoked in PE and suggests TLR9 as a therapeutic target.
62. Centlow M, Carninci P, Nemeth K, Mezey E, Brownstein M, et al. Placental expression profiling in preeclampsia: local overproduction of hemoglobin may drive pathological changes. Fertil Steril. 2008;90(5):1834-43.
63. Faivre B, Menu P, Labrude P, Vigneron C. Hemoglobin autooxidation/ oxidation mechanisms and methemoglobin prevention or reduction processes in the bloodstream. Literature review and outline of autooxidation reaction. Artificial cells, blood substitutes, and immobilization biotechnology. 1998;26(1):17-26.
64. Olsson MG, Centlow M, Rutardottir S, Stenfors I, Larsson J, et al. Increased levels of cell-free hemoglobin, oxidation markers, and the antioxidative heme scavenger alpha(1)-microglobulin in preeclampsia. Free radical biology & medicine. 2010;48(2):284-91.
65. • May K, Rosenlof L, Olsson MG, Centlow M, Morgelin M, et al. Perfusion of human placenta with hemoglobin introduces preeclampsia-like injuries that are prevented by alpha1-microglobulin. Placenta. 2011;32(4):323-32. Using an ex vivo placental perfusion model, this study tested the effectiveness of α1-microglobulin in preventing inflammatory and oxidative stress induced by free fetal heamoglobin. Simultaneous α1-microglobulin treatment inhibited placental haemoglobin leakage, morphological damage and upregulation of genes associated with immune response, apoptosis and oxidative stress. The results of this study underline the potential role of free fetal haemaglobin in PE pathophysiology and suggest a role for α1-microglobulin as a new PE therapeutic agent.
66. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(4):697-705.
67. Maynard SE, Min JY, Merchan J, Lim KH, Li J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. The Journal of clinical investigation. 2003;111(5):649-58.
68. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a Disease of the Maternal Endothelium The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease. Circulation. 2011;123(24):2856-69.
69. Maharaj ASR, Saint-Geniez M, Maldonado AE, D'Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006;168(2):639-48.
70. Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS. Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovascular research. 2011;89(3):671-9.
71. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, et al. Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia. Circulation. 2012;125(7):911-U199.
72. •• Rana S, Schnettler WT, Powe C, Wenger J, Salahuddin S, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertension in Pregnancy. 2013;32(2):189-201. The authors examined sFlt-1/PlGF ratio in women with PE. The results showed that PE women with a high sFlt-1/PlGF ratio were at increased risk of adverse outcomes and the need for earlier intervention. The study also shows that there is a group of PE women with low sFlt-1/PlGF ratio and suggested that levels of circulating angiogenic factors could be used to better classify women as having angiogenic PE who are at increased risk of adverse outcome and non-angiogenic PE women who require less intervention.
73. Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern-Fetal Neo M. 2012;25(5):498-507.
74. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592-4.
75. Rousseau A, Favier R, Van Dreden P. Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia? European journal of obstetrics, gynecology, and reproductive biology. 2009;146(1):46-9.
76. Estelles A, Gilabert J, Grancha S, Yamamoto K, Thinnes T, et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Thromb Haemostasis. 1998;79(3):500-8.
77. Teng Y, Jiang R, Lin Q, Ding C, Ye Z. The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients. Thromb Res. 2010;126(1):e41-5.
78. Germain SJ, Sacks GP, Sooranna SR, Sargent IL, Redman CW. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. Journal of Immunology. 2007;178(9):5949-56.
79. Yano Y, Shiba E, Kambayashi J, Sakon M, Kawasaki T, et al. The effects of calpeptin (a calpain specific inhibitor) on agonist induced microparticle formation from the platelet plasma membrane. Thromb Res. 1993;71(5):385-96.
80. Ahn YS, Jy W, Jimenez JJ, Horstman LL. More on: cellular microparticles: what are they bad or good for? J Thromb Haemost. 2004;2(7):1215-6.
81. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569-79.
82. Hedlund M, Stenqvist AC, Nagaeva O, Kjellberg L, Wulff M, et al. Human Placenta Expresses and Secretes NKG2D Ligands via Exosomes that Down-Modulate the Cognate Receptor Expression: Evidence for Immunosuppressive Function. Journal of Immunology. 2009;183(1):340-51.
83. Southcombe J, Tannetta D, Redman C, Sargent I. The immunomodulatory role of syncytiotrophoblast microvesicles. PloS one. 2011;6(5):e20245.
84. • Tannetta DS, Dragovic RA, Gardiner C, Redman CW, Sargent IL. Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin. PloS one. 2013;8(2):e56754. Syncytiotrophoblast microvesicles (STBM) and exosomes were prepared from preeclampsia and normal pregnancy placentas using ex vivo placental perfusion. Multi-colour flow cytometry and nanoparticle tracking analysis (NTA) were then used to analyse the size and phenotype of the vesicles. Results showed the vesicle preparations were highly enriched for STBM and that STBM carry functional anti-angiogenic Flt-1 and endoglin. NTA showed that STBM from PE placentas were larger, consistent with a shift toward more pro-inflammatory microvesicles and less exosome release in PE.
85. Messerli M, May K, Hansson SR, Schneider H, Holzgreve W, et al. Feto-maternal interactions in pregnancies: placental microparticles activate peripheral blood monocytes. Placenta. 2010;31(2):106-12.
86. Atay S, Gercel-Taylor C, Suttles J, Mor G, Taylor DD. Trophoblast-derived exosomes mediate monocyte recruitment and differentiation. Am J Reprod Immunol. 2011;65(1):65-77.
87. Atay S, Gercel-Taylor C, Taylor DD. Human trophoblast-derived exosomal fibronectin induces pro-inflammatory IL-1beta production by macrophages. Am J Reprod Immunol. 2011;66(4):259-69.
88. • Holder BS, Tower CL, Jones CJ, Aplin JD, Abrahams VM. Heightened pro-inflammatory effect of preeclamptic placental microvesicles on peripheral blood immune cells in humans. Biology of reproduction. 2012;86(4):103. This is the first paper to demonstrate increased proinflammatory activity of PE-derived placental microvesicles (MV) compared to those from normal placenta. Microvesicles collected from cultured preeclampsia placental explants stimulated a greater pro-inflammatory response by peripheral blood mononuclear cells (PBMC). PE MV also sensitised PBMC to a subsequent endotoxin challenge, suggesting that placental MV can modulate basal peripheral immune cell activation and responsiveness to endotoxin during normal pregnancy, and that in preeclampsia this effect is exacerbated.
89. Aly AS, Khandelwal M, Zhao J, Mehmet AH, Sammel MD, et al. Neutrophils are stimulated by syncytiotrophoblast microvillous membranes to generate superoxide radicals in women with preeclampsia. Am J Obstet Gynecol. 2004;190(1):252-8.
90. Smarason AK, Sargent IL, Starkey PM, Redman CW. The effect of placental syncytiotrophoblast microvillous membranes from normal and pre-eclamptic women on the growth of endothelial cells in vitro. Brit J Obstet Gynaec. 1993;100(10):943-9.
91. Gupta AK, Rusterholz C, Huppertz B, Malek A, Schneider H, et al. A comparative study of the effect of three different syncytiotrophoblast micro-particles preparations on endothelial cells. Placenta. 2005;26(1):59-66.
92. Hoegh AM, Tannetta D, Sargent I, Borup R, Nielsen FC, et al. Effect of syncytiotrophoblast microvillous membrane treatment on gene expression in human umbilical vein endothelial cells. BJOG: an international journal of obstetrics and gynaecology. 2006;113(11):1270-9.
93. Cockell AP, Learmont JG, Smarason AK, Redman CW, Sargent IL, et al. Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial function. Brit J Obstet Gynaec. 1997;104(2):235-40.
94. von Dadelszen P, Hurst G, Redman CW. Supernatants from co-cultured endothelial cells and syncytiotrophoblast microvillous membranes activate peripheral blood leukocytes in vitro. Hum Reprod. 1999;14(4):919-24.
95. Gardiner C, Tannetta DS, Simms CA, Harrison P, Redman CW, et al. Syncytiotrophoblast microvesicles released from pre-eclampsia placentae exhibit increased tissue factor activity. PloS one. 2011;6(10):e26313.
96. Redman CW, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, et al. (2012) Review: Does size matter? Placental debris and the pathophysiology of pre-eclampsia. Placenta.33 Suppl:S48-54.
97. Guller S, Tang Z, Ma YY, Di Santo S, Sager R, et al. Protein composition of microparticles shed from human placenta during placental perfusion: Potential role in angiogenesis and fibrinolysis in preeclampsia. Placenta. 2011;32(1):63-9.
98. Holder BS, Tower CL, Forbes K, Mulla MJ, Aplin JD, et al. Immune cell activation by trophoblast-derived microvesicles is mediated by syncytin 1. Immunology. 2012;136(2):184-91.
99. Reverdiau P, Jarousseau AC, Thibault G, Khalfoun B, Watier H, et al. Tissue factor activity of syncytiotrophoblast plasma membranes and tumoral trophoblast cells in culture. Thromb Haemost. 1995;73(1):49-54.
100. Ellis EM. Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacology & therapeutics. 2007;115(1):13-24.
101. Gommans WM, Berezikov E. Controlling miRNA regulation in disease. Methods Mol Biol. 2012;822:1-18.
102. Sargent I, Dragovic RA, Tannetta D, Redman C. Extracellular vesicles in normal pregnancy and pre-eclampsia. In: Harrison P, Gardiner C, Sargent I, editors. Extracellular vesicles in health and disease. UK: Pan Stanford Publishing; 2014.
103. •• Staff AC, Benton SJ, von Dadelszen P, Roberts JM, Taylor RN, et al. Redefining Preeclampsia Using Placenta-Derived Biomarkers. Hypertension. 2013;61(5):932-42. This is an important position paper, setting out a new strategy for the use of angiogenic factors to better define subgroups of PE women.
104. Banek CT, Bauer AJ, Gingery A, Gilbert JS. Timing of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat. American journal of physiology Regulatory, integrative and comparative physiology. 2012;303(6):R658-64.
105. Salles AMR, Galvao TF, Silva MT, Motta LCD, Pereira MG. (2012) Antioxidants for Preventing Preeclampsia: A Systematic Review. Sci World J.
106. El-Azab MF, Hazem RM, Moustafa YM. Role of simvastatin and/or antioxidant vitamins in therapeutic angiogenesis in experimental diabetic hindlimb ischemia: effects on capillary density, angiogenesis markers, and oxidative stress. European journal of pharmacology. 2012;690(1-3):31-41.
107. •• Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011;124(8):940-50. This study evaluated the use of dextran sulphate apheresis columns to lower circulating sFlt-1 levels in women with early onset PE. The columns removed sFlt-1 in a dose-dependent manner, which resulted in reduced proteinuria, stabilization of blood pressure and prolonging of pregnancy. Further studies are warranted to determine whether this intervention safely and effectively prolongs pregnancy and improves maternal and fetal outcomes.